The Role of ¹⁸F-FDG PET/CT in Multiple Myeloma Staging according to IMPeTUs: Comparison of the Durie–Salmon Plus and Other Staging Systems

Table 2

Characteristics of patients.

Number	Sex	Age	Myeloma type	IMPeTUs	DSS	DS Plus	RISS	Treatment
1	M	57	IgG λ	BM(4)A, F4.S.SP.ExtraSP(5), L4, PM, EM.EN(4)	B	IIIB	III	None
2	M	38	IgG κ	BM(3), F4.SP.ExtraSP(3), L4, EM.N.EN(4)	IIIA	IIIB	III	Chemotherapy
3	M	63	Nonsecretory	BM(2), F4.SP.ExtraSP(4), L4, PM, EM.EN(3)	IIIB	IIB	III	None
4	M	68	Light chain κ	BM(2), F4.SP.ExtraSP(4), L4, PM, EM.EN(3)	IIIB	IIIB	III	Chemotherapy
5	F	48	IgG κ	BM(2), F4.SP.ExtraSP(4), L4, PM	IIIA	IIA	I	Chemotherapy + IMIDs
6	M	55	IgG κ	BM(2), F4.SP.ExtraSP(4), L1, PM	IIIA	IIA	I	Chemotherapy + IMIDs
7	M	58	Light chain λ	BM(2), F3.SP.ExtraSP(4), L3, PM	IIIA	IA	II	Chemotherapy
8	M	63	IgG λ	BM(2), F4.S.SP.ExtraSP(4), L4	IIIA	IIIA	I	Chemotherapy
9	M	58	IgG κ	BM(3), F4.SP.ExtraSP(4), L4, PM, EM.N.EN(5)	IIIB	IIIB	III	Chemotherapy
10	F	42	IgG κ	BM(4), F1, L1	IIIA	IA	II	Chemotherapy + ASCT
11	M	60	Light chain κ	BM(3), F4.SP.ExtraSP(4), L4, EM.EN(3)	IIIA	IIA	II	Chemotherapy + ASCT
12	M	63	IgG κ	BM(2), F2.ExtraSP(4), L1	IIIA	IA	II	Chemotherapy
13	M	52	IgG λ	BM(3)A, F4.S.SP.ExtraSP(3), L2, EM.EN(3)	IIIA	IIIA	III	None
14	M	67	IgG λ	BM(4), F3.ExtraSP(4), L2	IIIA	IIA	II	Chemotherapy + allo-BMT
15	F	71	Light chain κ	BM(5), F4.SP.ExtraSP(5), L3, PM, EM.N(5)	IIIA	IIIB	II	Chemotherapy + radiotherapy
16	F	64	IgG κ	BM(3), F4.S.SP.ExtraSP(3), L3	IIIB	IIIB	III	Chemotherapy + IMIDs
17	F	67	IgG κ	BM(4)A, F4.SP.ExtraSP(4), L4	IIIB	IIIB	III	None
18	M	34	IgG κ	BM(3), F4.SP.ExtraSP(5), L3, PM, EM.EN(4)	IIIA	IIB	II	None
19	M	77	IgA κ	BM(2)A, F3.SP(4), L1, PM, EM.N.EN(3)	IIIA	IIA	II	None
20	M	72	IgG κ	BM(3), F3.SP.ExtraSP(4), L2, PM, EM.N(2)	IA	IIA	II	Chemotherapy
21	M	60	IgG λ	BM(3), F4.SP.ExtraSP(5), L3, PM, EM.N(5)	IIIA	IIB	II	Chemotherapy + IMIDs
22	M	73	Light chain κ	BM(3), F4.SP.ExtraSP(5), L2, EM.EN(5)	IIIB	IIIB	III	Chemotherapy + IMIDs
23	M	60	IgD λ	BM(2), F2.SP(4), L2	IIIA	IA	III	Chemotherapy + IMIDs
24	M	59	Light chain κ	BM(3), F3.SP.ExtraSP(5), L1, PM, EM.N(5)	IIA	IB	I	None
25	M	64	IgG κ	BM(2), F2.SP(4), L4, PM	IIB	IIB	II	Chemotherapy + IMIDs
26	F	57	IgG λ	BM(4)A, F4.SP.ExtraSP(4), L4, PM, EM.N(5)EN(4)	IIIA	IIIB	II	Chemotherapy
27	F	76	Light chain κ	BM(4)A, F4.SP.ExtraSP(5), L4, PM, EM.EN(5)	IIIA	IIIB	III	None
28	F	58	IgA λ	BM(4)A, F4.S.SP.ExtraSP(5), L4, EM.EN(5)	IIIA	IIIB	III	Chemotherapy + IMIDs
29	F	47	Light chain κ	BM(2), F2.SP(5), L2, PM, EM.EN(5)	IIIA	IB	II	Chemotherapy + radiotherapy
30	M	69	IgG λ	BM(2), F2.SP(2), L2, EM.EN(4)	IIIB	IB	II	Chemotherapy
31	M	65	IgG λ	BM(2), PM, EM.EN(4)	IIIA	IB	III	Chemotherapy + ASCT
32	F	53	IgD λ	BM(4)A, EM.EN(4)	IIIB	IB	II	Chemotherapy + IMIDs
33	M	50	IgG λ	BM(5)A, F4.S.SP.ExtraSP(5), L4, EM.EN(4)	IIIB	IIIB	III	Chemotherapy

ASCT: autologous stem cell transplant; IMIDs: immunomodulatory drugs; BM: bone marrow; F: focal bone lesions; S: skull; Sp: spine; L: lytic lesion; Fr: fracture; EM: EMD; PM: paramedullary disease; N: nodal disease; EN: extranodal disease.